ArticlePharmaceuticals (Basel, Switzerland)2025

Development of Clinical-Grade Durvalumab-680LT and Nivolumab-800CW for Multispectral Fluorescent Imaging of the PD-1/PD-L1 Axis of the Immune Checkpoint Pathway.

Henrik K Huizinga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.